Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Anti-nociception
Bifunctional ligand
MOP receptor
NOP receptor
Non-human primate
Nonpeptide
ligand
Peptide ligand
Spinal cord
Journal
Current topics in medicinal chemistry
ISSN: 1873-4294
Titre abrégé: Curr Top Med Chem
Pays: United Arab Emirates
ID NLM: 101119673
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
01
2020
revised:
10
04
2020
accepted:
14
04
2020
pubmed:
10
5
2020
medline:
2
7
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Despite similar distribution patterns and intracellular events observed in the nociceptin/ orphanin FQ peptide (NOP) receptor and other opioid receptors, NOP receptor activation displays unique pharmacological profiles. Several researchers have identified a variety of peptide and nonpeptide ligands to determine the functional roles of NOP receptor activation and observed that NOP receptor- related ligands exhibit pain modality-dependent pain processing. Importantly, NOP receptor activation results in anti-nociception and anti-hypersensitivity at the spinal and supraspinal levels regardless of the experimental settings in non-human primates (NHPs). Given that the NOP receptor agonists synergistically enhance mu-opioid peptide (MOP) receptor agonist-induced anti-nociception, it has been hypothesized that dual NOP and MOP receptor agonists may display promising functional properties as analgesics. Accumulating evidence indicates that the mixed NOP/opioid receptor agonists demonstrate favorable functional profiles. In NHP studies, bifunctional NOP/MOP partial agonists (e.g., AT-121, BU08028, and BU10038) exerted potent anti-nociception via NOP and MOP receptor activation; however, dose-limiting adverse effects associated with the MOP receptor activation, including respiratory depression, itch sensation, physical dependence, and abuse liability, were not observed. Moreover, a mixed NOP/opioid receptor agonist, cebranopadol, presented promising outcomes in clinical trials as a novel analgesic. Collectively, the dual agonistic actions on NOP and MOP receptors, with appropriate binding affinities and efficacies, may be a viable strategy to develop innovative and safe analgesics.
Identifiants
pubmed: 32384033
pii: CTMC-EPUB-106452
doi: 10.2174/1568026620666200508082615
pmc: PMC7720806
mid: NIHMS1649230
doi:
Substances chimiques
Analgesics, Opioid
0
BU10038
0
Isoquinolines
0
Ligands
0
Phenylpropionates
0
Receptors, Opioid
0
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2878-2888Subventions
Organisme : NIDA NIH HHS
ID : R01 DA032568
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR069861
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA044450
Pays : United States
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Neuroreport. 1996 Sep 2;7(13):2092-4
pubmed: 8930965
J Neuroimmunol. 1998 Jan;81(1-2):184-92
pubmed: 9521621
Proteins. 2012 Aug;80(8):1948-61
pubmed: 22489047
Handb Exp Pharmacol. 2019;254:37-67
pubmed: 31119463
J Comp Neurol. 1999 Oct 4;412(4):563-605
pubmed: 10464356
Nature. 2012 Mar 21;485(7398):327-32
pubmed: 22437504
Br J Pharmacol. 2015 Jul;172(13):3302-12
pubmed: 25752320
J Neurosci. 1996 Nov 1;16(21):6657-64
pubmed: 8824306
Peptides. 2000 Jul;21(7):961-7
pubmed: 10998529
Brain Res. 1997 Apr 18;754(1-2):329-32
pubmed: 9134994
FEBS Lett. 1994 Jul 4;348(1):75-9
pubmed: 8026588
Brain Res. 2004 Jan 30;997(1):24-9
pubmed: 14715146
Nature. 1995 Oct 12;377(6549):532-5
pubmed: 7566152
Peptides. 2018 Jan;99:195-204
pubmed: 29031796
Br J Pharmacol. 2018 Jul;175(14):2857-2868
pubmed: 28378462
FEBS Lett. 1994 Apr 18;343(1):42-6
pubmed: 8163014
Br J Pharmacol. 1996 Nov;119(6):1081-3
pubmed: 8937708
Br J Pharmacol. 1996 Dec;119(8):1614-8
pubmed: 8982509
J Pharmacol Exp Ther. 2009 Dec;331(3):946-53
pubmed: 19713488
Br J Anaesth. 2018 Nov;121(5):1105-1114
pubmed: 30336855
Biochem Biophys Res Commun. 2000 Nov 19;278(2):493-8
pubmed: 11097863
J Clin Pharm Ther. 2017 Feb;42(1):8-17
pubmed: 27778406
Eur J Pharmacol. 2017 Jan 5;794:115-126
pubmed: 27871910
J Nucl Med. 2011 Oct;52(10):1638-45
pubmed: 21880575
Eur J Pharmacol. 1999 Apr 9;370(2):109-16
pubmed: 10323258
Brain Res. 2000 Feb 28;857(1-2):212-8
pubmed: 10700570
J Neurophysiol. 2008 Sep;100(3):1420-32
pubmed: 18562551
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8666-70
pubmed: 8710928
Neurosci Lett. 1998 Jun 26;250(1):21-4
pubmed: 9696056
Psychopharmacology (Berl). 2014 Apr;231(7):1377-87
pubmed: 24217900
J Comp Neurol. 1996 Apr 29;368(2):229-51
pubmed: 8725304
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5511-8
pubmed: 27573832
J Neurophysiol. 1997 Dec;78(6):3351-8
pubmed: 9405549
Eur J Pharmacol. 1996 Sep 5;311(1):R3-5
pubmed: 8884244
Psychopharmacology (Berl). 2011 Jan;213(1):53-60
pubmed: 20852848
J Clin Pharm Ther. 2014 Dec;39(6):577-83
pubmed: 25070601
Nature. 2012 Mar 21;485(7398):321-6
pubmed: 22437502
Peptides. 2000 Jul;21(7):907-17
pubmed: 10998524
Br J Pharmacol. 1996 May;118(2):205-7
pubmed: 8735615
Neuroscience. 1997 Nov;81(1):249-54
pubmed: 9300417
Br J Pharmacol. 2018 Jul;175(13):2662-2675
pubmed: 29582417
Eur J Med Chem. 2000 Sep;35(9):839-51
pubmed: 11006485
Br J Pharmacol. 1997 Jun;121(3):425-32
pubmed: 9179383
Nature. 2012 May 16;485(7398):400-4
pubmed: 22596164
Pain. 2014 Sep;155(9):1821-8
pubmed: 24968803
Neuropsychopharmacology. 2009 Aug;34(9):2088-96
pubmed: 19279568
Neurosci Lett. 1997 Feb 21;223(2):113-6
pubmed: 9089686
Bioorg Med Chem. 2014 Jul 15;22(14):3703-12
pubmed: 24878361
Br J Pharmacol. 1999 Aug;127(7):1712-8
pubmed: 10455330
Pain. 2004 Jul;110(1-2):236-45
pubmed: 15275773
Pharmacol Rev. 2016 Apr;68(2):419-57
pubmed: 26956246
J Med Chem. 2016 Aug 11;59(15):7011-28
pubmed: 26878436
Eur J Pharmacol. 1998 Sep 4;356(2-3):R1-3
pubmed: 9774260
J Med Chem. 2011 Oct 13;54(19):6531-7
pubmed: 21866885
Br J Pharmacol. 2015 Jan;172(2):317-23
pubmed: 24528283
FEBS Lett. 1994 Jun 27;347(2-3):284-8
pubmed: 8034019
Pain. 2010 Jan;148(1):107-13
pubmed: 19945794
J Neurosci Res. 2007 May 15;85(7):1478-88
pubmed: 17387690
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40
pubmed: 8393575
Nature. 2012 May 16;485(7398):395-9
pubmed: 22596163
Neuroreport. 1997 May 27;8(8):1967-70
pubmed: 9223086
J Pharmacol Exp Ther. 2014 Jun;349(3):535-48
pubmed: 24713140
Adv Pharmacol. 2016;75:217-43
pubmed: 26920014
FEBS Lett. 1997 Feb 10;403(1):91-4
pubmed: 9038367
J Pharmacol Exp Ther. 2008 Aug;326(2):672-82
pubmed: 18492950
Handb Exp Pharmacol. 2019;254:323-343
pubmed: 30879202
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4938-43
pubmed: 10758169
Life Sci. 2009 Jul 31;85(5-6):206-10
pubmed: 19523963
Br J Pharmacol. 2014 Aug;171(16):3777-800
pubmed: 24762001
Br J Pharmacol. 2015 Jul;172(14):3661-70
pubmed: 25828800
Pain. 1998 Jun;76(3):385-93
pubmed: 9718257
CNS Neurosci Ther. 2011 Jun;17(3):178-98
pubmed: 20497197
Mol Pharmacol. 2001 Mar;59(3):612-8
pubmed: 11179457
AAPS J. 2005 Oct 05;7(2):E345-52
pubmed: 16353914
Br J Anaesth. 2019 Jun;122(6):e146-e156
pubmed: 30916003
Bioorg Med Chem. 2008 Oct 15;16(20):9261-7
pubmed: 18818087
N Engl J Med. 2016 Mar 31;374(13):1253-63
pubmed: 27028915
Science. 1995 Nov 3;270(5237):792-4
pubmed: 7481766
Results Probl Cell Differ. 2008;46:1-25
pubmed: 18193175
Life Sci. 1996;59(1):PL23-9
pubmed: 8684262
Peptides. 2007 Jun;28(6):1240-51
pubmed: 17532097
Eur J Pharmacol. 2001 Jan 19;412(1):39-44
pubmed: 11166734
Sci Rep. 2015 Jun 29;5:11676
pubmed: 26119696
Handb Exp Pharmacol. 2019;254:17-36
pubmed: 30689091
Brain Res. 2005 May 10;1043(1-2):214-7
pubmed: 15862535
Pain. 2017 Sep;158(9):1813-1824
pubmed: 28644196
Neuroscience. 2003;118(2):513-23
pubmed: 12699786
J Comp Neurol. 1999 Apr 19;406(4):503-47
pubmed: 10205026
Br J Pharmacol. 2013 Jan;168(1):151-62
pubmed: 22827708
Handb Exp Pharmacol. 2019;254:165-186
pubmed: 31119465
Ann Intern Med. 2014 Jan 7;160(1):38-47
pubmed: 24217469
Nat Rev Drug Discov. 2008 Aug;7(8):694-710
pubmed: 18670432
J Med Chem. 1999 Dec 16;42(25):5061-3
pubmed: 10602690
Pain. 2016 Sep;157(9):1960-9
pubmed: 27127846
J Pharmacol Exp Ther. 2012 Oct;343(1):72-81
pubmed: 22743574
Pain. 2006 Sep;124(1-2):100-8
pubmed: 16697109
J Pain. 2009 May;10(5):509-16
pubmed: 19231294
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
Am J Psychiatry. 2016 Jan;173(1):18-26
pubmed: 26337039
J Neurosci Res. 2002 May 15;68(4):496-500
pubmed: 11992477
Peptides. 2000 Jul;21(7):1023-9
pubmed: 10998536
J Pharmacol Exp Ther. 1999 Oct;291(1):308-13
pubmed: 10490918
Neuroscience. 2003;121(3):629-40
pubmed: 14568023
Sci Transl Med. 2018 Aug 29;10(456):
pubmed: 30158150
Anesthesiology. 1997 Nov;87(5):1145-52
pubmed: 9366467
J Med Chem. 1997 Jun 6;40(12):1789-93
pubmed: 9191955
Brain Res. 2001 Jun 29;905(1-2):127-33
pubmed: 11423087
Curr Med Chem. 2018;25(20):2353-2384
pubmed: 29332567
Eur J Pain. 2019 Mar;23(3):577-588
pubmed: 30365202
Mol Pharmacol. 1993 Jul;44(1):8-12
pubmed: 8393525
ACS Med Chem Lett. 2014 Jun 24;5(8):857-62
pubmed: 25147603
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12048-52
pubmed: 1334555
J Support Oncol. 2012 Nov-Dec;10(6):209-19
pubmed: 22809652
Science. 1992 Dec 18;258(5090):1952-5
pubmed: 1335167
J Med Chem. 2014 May 22;57(10):4049-57
pubmed: 24761755
N Engl J Med. 2017 Jul 27;377(4):391-394
pubmed: 28564549
Clin Pharmacokinet. 2018 Jan;57(1):31-50
pubmed: 28623508
ACS Chem Neurosci. 2013 Feb 20;4(2):214-24
pubmed: 23421672
J Pharmacol Exp Ther. 2011 Mar;336(3):952-61
pubmed: 21177476
Biochem Biophys Res Commun. 1994 Dec 15;205(2):1353-7
pubmed: 7802669
FEBS Lett. 1994 Mar 14;341(1):33-8
pubmed: 8137918
Handb Exp Pharmacol. 2019;254:367-398
pubmed: 30927089
Structure. 2015 Dec 1;23(12):2291-2299
pubmed: 26526853
Br J Pharmacol. 2014 Sep;171(17):4138-53
pubmed: 24903280